Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Acthib, Pentacel
- Generic Name
- Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
- DrugBank Accession Number
- DB10076
- Background
Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type b. H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis. The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid 1. The toxoid antigen is purified and toxin-inactivated.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated / Toxoid / Conjugate - Synonyms
- Haemophilus influenzae type B strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ActHIB Kit 10 ug/0.5mL Intramuscular Sanofi Pasteur Inc. 1993-03-30 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Act-hib Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg) Kit; Powder, for solution Intramuscular Sanofi Pasteur Limited 1992-12-31 Not applicable Canada 
Infanrix-hexa Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (8 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (10 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 lf / 0.5 mL) + Hepatitis B Vaccine (Recombinant) (10 mcg / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL) Suspension Intramuscular Glaxosmithkline Inc 2008-12-04 Not applicable Canada Menhibrix Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL) Injection, powder, lyophilized, for solution Intramuscular GlaxoSmithKline Biologicals SA 2013-09-03 2013-11-27 US Menhibrix Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL) Kit Intramuscular GlaxoSmithKline Biologicals SA 2013-09-03 2017-09-17 US Pediacel Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 mcg / 0.5 mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (3 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (20 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 lf / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL) Suspension Intramuscular Sanofi Pasteur Limited 2007-10-04 Not applicable Canada Pentacel Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL) Intramuscular Sanofi Pasteur Inc. 2008-06-20 Not applicable US Pentacel Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL) Intramuscular Sanofi Pasteur Inc. 2008-06-20 Not applicable US PENTAXIM 0,5 ML (IM ENJEKSİYON) SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml) Injection, powder, for suspension Intramuscular SANOFİ PASTEUR AŞI TİC. A.Ş. 2020-08-14 Not applicable Turkey 
Prohibit Inj Vaccine Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (25 mcg / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (23 mcg / 0.5 mL) Liquid Intramuscular Aventis Pasteur Limited 1988-12-31 2000-05-27 Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FLV5I5W26R
- CAS number
- Not Available
References
- General References
- Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Acute Lymphoblastic Leukemia (ALL) 1 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus 1 4 Completed Treatment Pain 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B 1 3 Completed Prevention Bacterial Infections / Neisseria Meningitidis / Virus Diseases 1 3 Completed Prevention Bacterial Infections / Virus Diseases 2 3 Completed Prevention Diphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus 1 3 Completed Prevention Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Pertussis / Poliomyelitis / Tetanus 4 3 Completed Prevention Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Pertussis / Tetanus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit; powder, for solution Intramuscular Injection, powder, for solution Intramuscular 10 µg/0.5mL Kit Intramuscular 10 ug/0.5mL Injection, powder, lyophilized, for solution Intramuscular Kit Intramuscular Suspension Intramuscular Injection, powder, for suspension Intramuscular Liquid Intramuscular Injection, suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 21:23 / Updated at November 28, 2021 16:22